In addition to accumulating evidence demonstrating the beneficial therapeutic effect of blocking the m6A epitranscriptomic landscape in GSCs63, our study further emphasizes the potential for therapeutic strategies preventatively targeting mutant p53/SVIL/MLL1-upregulated YTHDF2 expression in LFS patients as well as treating gliomas harboring p53 missense mutations. This evidence concerns the gene KMT2A and central nervous system cancer.